People news: Vertex and Amgen

Share this article:

Vertex CEO Matthew Emmens is stepping down from that post after the company's best year ever and amid skyrocketing sales of its hepatitis C drug Incivek. Emmens will stay on as executive chairman through May and will continue to sit on the board of directors thereafter. Replacing him as CEO is Dr. Jeffrey Leiden, a Vertex board member, venture capitalist, practicing cardiologist and molecular biologist.

Kevin Sharer will retire as Amgen's CEO in May, to be replaced by Robert Bradway, the firm's current president and chief operating officer . Bradway will also take over the chairman role once Sharer leaves that position at the end of 2012. In addition, EVP for R&D Dr. Roger M. Perlmutter will retire effective Feb. 12 and will be succeeded by Dr. Sean Harper, the company's chief medical officer.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in People Moves

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in People Moves

Monday Moves: October 20

Promotions and hires for agencies and manufacturers

Monday Moves: September 29

Promotions and hires for agencies and manufacturers

Monday Moves—July 21, 2014

Hires and promotions for Manufacturers, Agencies and Media